Substance Use And Addiction - USMLE Step 2

SECTION 1

Historical Context & Evolving Models of Addiction

The understanding of substance use and addiction has undergone profound transformation over centuries. For much of recorded history, excessive substance use was viewed exclusively through a moral lens—individuals who could not control their drinking or opium consumption were considered weak-willed or sinful. This moral model dominated medical and social discourse well into the twentieth century, informing punitive policies rather than therapeutic interventions. The shift toward understanding addiction as a medical condition with identifiable neurobiological substrates represents one of the most significant paradigm changes in the history of psychiatry, with direct implications for how clinicians approach diagnosis, treatment, and patient advocacy on the USMLE Step 2 and in clinical practice.

1784 • Rush's Disease Concept

Benjamin Rush, a signer of the Declaration of Independence and physician, published An Inquiry into the Effects of Ardent Spirits, arguing that chronic drunkenness was a disease of the will rather than a simple moral failing—an early medical reframing of addiction.

1935 • Founding of Alcoholics Anonymous

Bill Wilson and Dr. Bob Smith founded AA, popularizing the twelve-step model and the concept that alcoholism is a chronic, relapsing condition requiring ongoing support—a framework still central to many recovery programs.

1975 • Endogenous Opioid System Discovery

John Hughes and Hans Kosterlitz identified enkephalins, endogenous opioid peptides, revealing that the brain possesses its own reward and pain-modulating system that exogenous substances hijack.

1997 • NIDA Brain Disease Model

Alan Leshner, then director of NIDA, published a landmark article defining addiction as a "chronic, relapsing brain disease," catalyzing federal research funding and destigmatization efforts.

2013 • DSM-5 Reclassification

The DSM-5 replaced the categorical distinction between "substance abuse" and "substance dependence" with a single, dimensional substance use disorder (SUD) diagnosis graded by severity (mild, moderate, severe), reflecting contemporary neuroscience and clinical evidence.

The central clinical question that these historical developments converge upon is this: how does repeated substance exposure transform voluntary use into compulsive behavior, and what diagnostic and therapeutic tools allow clinicians to intervene at each stage of this progression? Answering this question requires integrating neurobiology, pharmacology, behavioral science, and the structured diagnostic criteria tested on the USMLE Step 2.

SECTION 2

Core Principles & DSM-5 Diagnostic Framework

The DSM-5 defines a substance use disorder as a cluster of cognitive, behavioral, and physiological symptoms indicating continued substance use despite significant substance-related problems. The diagnosis requires meeting at least two of eleven criteria within a twelve-month period, with severity graded as mild (2–3 criteria), moderate (4–5 criteria), or severe (6+ criteria). Importantly, the DSM-5 eliminated the prior distinction between abuse and dependence, recognizing that these represent points on a continuum rather than discrete entities.

Impaired Control (Criteria 1–4)

Taking larger amounts or over longer periods than intended; persistent desire or unsuccessful efforts to cut down; excessive time spent obtaining, using, or recovering; and craving or strong urge to use the substance.

Social Impairment (Criteria 5–7)

Failure to fulfill major role obligations at work, school, or home; continued use despite persistent social or interpersonal problems caused or exacerbated by the substance; and important activities given up or reduced because of substance use.

Risky Use (Criteria 8–9)

Recurrent substance use in physically hazardous situations (e.g., driving while intoxicated) and continued use despite knowledge of having a persistent physical or psychological problem likely caused by the substance.

Pharmacological (Criteria 10–11)

Tolerance—needing increased amounts for desired effect or diminished effect at the same dose. Withdrawal—characteristic syndrome on cessation, or using to relieve/avoid withdrawal. Note: tolerance and withdrawal alone do not qualify for SUD diagnosis when substances are taken as prescribed.

✦

KEY TAKEAWAY

Think of the DSM-5 SUD criteria like a clinical severity thermometer: the more criteria met, the higher the reading. Unlike a binary fever/no-fever determination, the DSM-5 embraces a dimensional model that captures the full spectrum from mild misuse to severe addiction. This mirrors other chronic diseases—just as hypertension is staged by blood pressure readings, SUD is staged by criterion count. On the USMLE, remember that meeting only one criterion is insufficient for diagnosis.

SECTION 3

Neurobiology of Addiction — The Reward Circuitry

The mesocorticolimbic dopamine system is the principal neural substrate underlying the reinforcing effects of virtually all drugs of abuse. Dopaminergic neurons originating in the ventral tegmental area (VTA) project to the nucleus accumbens (NAc) and the prefrontal cortex (PFC). Natural rewards such as food, sex, and social interaction produce modest, physiological dopamine surges in the NAc, reinforcing survival behaviors. Substances of abuse produce supraphysiological dopamine release—cocaine and amphetamines may elevate synaptic dopamine three to ten times above baseline—overwhelming the system and driving neuroplastic changes that underlie compulsive drug-seeking.

The mesocorticolimbic reward circuit. Dopaminergic (DA) projections from the VTA innervate the NAc (reward salience), the PFC (executive control), and the amygdala (stress/emotional memory). Chronic substance use produces supraphysiological DA surges in the NAc while simultaneously impairing PFC top-down inhibition—a neurobiological recipe for compulsive use.

With chronic exposure, several neuroadaptive processes unfold. First, dopamine receptor downregulation in the NAc diminishes the hedonic impact of both the substance and natural rewards, driving escalation of use (tolerance). Second, the extended amygdala becomes hyperactive, recruiting stress neurotransmitters (CRF, norepinephrine, dynorphin) that produce dysphoria during abstinence—the neurobiological basis of withdrawal-driven relapse. Third, prefrontal cortical hypofunction impairs executive control over drug-seeking behavior. These three stages—binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation (craving)—constitute the three-stage cycle of addiction proposed by Koob and Volkow, a model frequently tested on board examinations.

SECTION 4

Mechanisms of Major Substance Classes

Different substance classes produce their reinforcing and toxic effects through distinct pharmacological mechanisms, and understanding these mechanisms is essential for both diagnosis and treatment on Step 2. The following deep-dive focuses on the substances most commonly tested: alcohol, opioids, stimulants, sedative-hypnotics, and cannabis.

Alcohol

Ethanol enhances GABA-A receptor function (inhibitory) and antagonizes NMDA glutamate receptors (excitatory), producing its sedative, anxiolytic, and amnestic effects. Chronic use leads to compensatory upregulation of NMDA receptors and downregulation of GABA-A receptors. Upon abrupt cessation, this neuroadaptation manifests as the hyperexcitable state of alcohol withdrawal—tremor, diaphoresis, tachycardia, seizures, and potentially delirium tremens (DTs), which carries a mortality rate of up to 5% without treatment. The CIWA-Ar scale guides benzodiazepine dosing in monitored settings. Long-term pharmacotherapy options include naltrexone (opioid antagonist reducing reward), acamprosate (glutamate modulator reducing craving), and disulfiram (aldehyde dehydrogenase inhibitor causing aversive reaction with alcohol).

Opioids

Opioids—including heroin, fentanyl, oxycodone, and morphine—act as agonists at mu (μ) opioid receptors, producing analgesia, euphoria, respiratory depression, and miosis. Opioid intoxication is recognized by the classic triad of altered mental status, miosis, and respiratory depression. The antidote is naloxone (IV/IM/intranasal), a competitive μ-receptor antagonist with a shorter half-life than most opioids, necessitating observation for re-sedation. Withdrawal is intensely uncomfortable but not life-threatening—presenting with mydriasis, lacrimation, rhinorrhea, piloerection, diarrhea, and myalgias. FDA-approved medications for opioid use disorder (MOUD) include methadone (full μ agonist), buprenorphine (partial μ agonist with ceiling effect), and naltrexone (μ antagonist).

Stimulants

Cocaine blocks dopamine, norepinephrine, and serotonin reuptake transporters; amphetamines additionally promote catecholamine release from presynaptic terminals. Both produce sympathomimetic toxicity: hypertension, tachycardia, hyperthermia, mydriasis, agitation, and potential for seizures, MI, and stroke. There are currently no FDA-approved pharmacotherapies for stimulant use disorder; management is primarily behavioral (contingency management, CBT). Stimulant withdrawal produces a "crash" characterized by hypersomnia, hyperphagia, dysphoria, and fatigue—unpleasant but not medically dangerous.

⚠

HIGH-YIELD PEARL

Only two substance classes produce life-threatening withdrawal: alcohol and sedative-hypnotics (benzodiazepines, barbiturates). Both act on GABA systems; abrupt cessation can produce seizures and death. Opioid withdrawal, while miserable, is not fatal in otherwise healthy individuals.

SECTION 5

Intoxication & Withdrawal — Clinical Recognition

Recognizing the clinical presentations of intoxication and withdrawal syndromes is among the highest-yield topics for the USMLE Step 2. The following comprehensive table and accompanying diagram provide a systematic approach to pattern recognition across the major substance classes.

Side-by-side comparison of intoxication and withdrawal presentations for six major substance classes. Note the autonomic pattern inversion between intoxication and withdrawal for CNS depressants (alcohol, benzodiazepines)—intoxication suppresses sympathetic activity, while withdrawal produces a hyperadrenergic state.

Substance	Pupil Finding	Life-Threatening?	Acute Treatment
Alcohol withdrawal	Normal or mydriasis	YES — seizures, DTs	Benzodiazepines (lorazepam, chlordiazepoxide); CIWA-Ar protocol
Opioid intoxication	Miosis (pinpoint)	YES — respiratory arrest	Naloxone (may need repeat doses)
Opioid withdrawal	Mydriasis	No (uncomfortable, not fatal)	Buprenorphine, methadone, clonidine for symptom relief
Stimulant intoxication	Mydriasis	YES — MI, stroke, hyperthermia	Benzodiazepines for agitation; avoid β-blockers (unopposed α)
Benzo withdrawal	Normal or mydriasis	YES — seizures	Gradual taper with long-acting benzodiazepine
Cannabis intoxication	Conjunctival injection, normal pupils	No	Supportive; benzodiazepines if severe anxiety

High-Yield Intoxication & Withdrawal Summary for USMLE Step 2

SECTION 6

Worked Clinical Vignette — Opioid Use Disorder

The following worked example illustrates a typical Step 2 clinical vignette involving substance use disorder diagnosis and management, demonstrating the systematic approach expected on board examinations.

Clinical Vignette: 28-Year-Old Male in the Emergency Department

1
Step 1 — Identify the Clinical Presentation

A 28-year-old male is brought to the ED by EMS after being found unresponsive in a park. Vitals: HR 52, BP 90/60, RR 6, SpO₂ 82% on room air. Examination reveals pinpoint pupils bilaterally and track marks on bilateral antecubital fossae. He is cyanotic with shallow respirations.

Classic triad: respiratory depression + miosis + altered mental status = opioid intoxication
2
Step 2 — Initiate Acute Management

The immediate priority is airway management and reversal of opioid effects. Administer naloxone 0.4–2 mg IV. Naloxone has a half-life of 30–90 minutes, which is shorter than most opioids (especially methadone or extended-release formulations). The patient must be observed for re-sedation and repeat dosing may be needed. Provide supplemental O₂ and prepare for possible bag-valve-mask ventilation.

Naloxone administered; patient regains consciousness, RR increases to 14, SpO₂ improves to 97%.
3
Step 3 — Assess for Substance Use Disorder

Once stabilized, a thorough history reveals: using IV heroin daily for 2 years; multiple unsuccessful attempts to quit; spending most of his day obtaining, using, or recovering from heroin; lost his job; continued use despite two prior overdoses and a skin abscess; uses more heroin than intended; experiences intense cravings; and has tolerance and withdrawal symptoms. Count the DSM-5 criteria met.

At least 9 of 11 criteria met → Severe Opioid Use Disorder
4
Step 4 — Plan Long-Term Treatment

Evidence-based guidelines strongly recommend medication for opioid use disorder (MOUD) as first-line treatment, as it reduces overdose mortality by approximately 50%. Options include methadone (dispensed through federally regulated opioid treatment programs), buprenorphine/naloxone (can be prescribed in office settings), or extended-release naltrexone (requires complete detoxification first). Combine with psychosocial interventions (CBT, contingency management, peer support). Screen for comorbid psychiatric disorders (depression, PTSD), hepatitis C, and HIV.

Initiate buprenorphine/naloxone in the ED (per updated guidelines) once the patient enters mild-moderate withdrawal (COWS ≥ 8); refer for ongoing MOUD and psychosocial treatment.

SECTION 7

Pharmacotherapy Comparison — Strengths & Limitations

Pharmacological interventions for substance use disorders vary significantly in their mechanisms, clinical contexts, and evidence bases. The following table compares the most commonly tested medications across the major substance classes, emphasizing practical considerations relevant to both board examinations and clinical rotations.

Medication	Mechanism	Indication	Key Limitation
Naltrexone (oral/IM)	μ-opioid receptor antagonist	Alcohol use disorder; opioid use disorder	Requires full opioid detox before initiation; poor adherence with oral form
Acamprosate	Modulates NMDA/glutamate; restores excitatory/inhibitory balance	Alcohol use disorder (maintenance of abstinence)	Contraindicated in severe renal impairment (CrCl < 30); TID dosing reduces adherence
Disulfiram	Inhibits aldehyde dehydrogenase → acetaldehyde accumulation with alcohol	Alcohol use disorder (aversion therapy)	Requires high motivation/supervised administration; hepatotoxicity risk; dangerous if patient drinks
Buprenorphine/Naloxone	Partial μ agonist (ceiling effect) + naloxone (deters IV misuse)	Opioid use disorder	Can precipitate withdrawal if initiated too early; requires patient be in mild withdrawal first
Methadone	Full μ agonist; also NMDA antagonist	Opioid use disorder; pain management	QTc prolongation; dispensed only at licensed OTPs; risk of respiratory depression
Varenicline	Partial agonist at nicotinic α₄β₂ receptors	Tobacco use disorder	Nausea common; earlier black box warning for neuropsychiatric events was removed in 2016

Commonly Tested Pharmacotherapies for Substance Use Disorders

✦

KEY TAKEAWAY

Think of medications for substance use disorders as fitting into three mechanistic strategies, analogous to engineering solutions for a dam overflow: replacement therapy (methadone, nicotine replacement) provides a controlled flow to prevent catastrophic breach; blockade therapy (naltrexone) seals the reward pathway so that even if the substance arrives, it cannot exert its reinforcing effect; and aversion therapy (disulfiram) installs an alarm system that punishes any attempt to open the floodgates. The choice depends on patient motivation, comorbidities, and practical access.

SECTION 8

Screening, Brief Intervention & Comorbid Psychiatry

The clinical evaluation of substance use extends well beyond emergency presentations. Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based, public health approach endorsed by SAMHSA and frequently tested on Step 2. It involves universal screening in primary care and emergency settings using validated tools, followed by a brief motivational intervention for at-risk patients, and referral for specialized treatment when needed. Understanding the interplay between substance use disorders and comorbid psychiatric illness—so-called dual diagnosis—is essential, as approximately 50% of individuals with a severe mental illness also have a co-occurring SUD.

Concept	Step 2 Focus	Advanced / Step 3 Level
Screening tools	CAGE (alcohol), AUDIT-C, DAST-10; know cutoff scores and sensitivity/specificity	TAPS tool; integration into EHR-based clinical decision support; population-level implementation
Motivational Interviewing (MI)	Stages of Change model (Prochaska); OARS technique; non-confrontational, patient-centered approach	MI fidelity assessment; integration with CBT and contingency management in stepped-care models
Dual Diagnosis	Identify substance-induced vs. independent psychiatric disorders; wait 2–4 weeks of sobriety before diagnosing primary mood/anxiety disorder	Integrated treatment models; pharmacogenomics guiding medication selection in comorbid populations
Harm Reduction	Needle exchange programs, naloxone distribution, supervised consumption sites; understand public health rationale	Health policy analysis; cost-effectiveness modeling; overdose prevention center outcomes data

Step 2 vs. Advanced Concepts in Substance Use Assessment

💡

USMLE PEARL — Substance-Induced vs. Independent Psychiatric Disorders

A common Step 2 distractor involves differentiating substance-induced psychiatric disorders from independent (primary) psychiatric illness. Key distinguishing features: substance-induced disorders have onset during intoxication or withdrawal, improve with sustained abstinence (typically 2–4 weeks), and lack a psychiatric history predating substance use. If symptoms persist well beyond the expected duration of intoxication/withdrawal, consider an independent psychiatric disorder requiring its own treatment.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A 34-year-old man is brought to the emergency department by his friends after they found him unresponsive at a party. On examination, he has pinpoint pupils, a respiratory rate of 6 breaths/min, SpO2 of 82% on room air, and decreased bowel sounds. Multiple track marks are noted on his forearms. His temperature is 36.5°C (97.7°F), blood pressure is 100/60 mmHg, and pulse is 55/min. Airway is patent and a nurse is preparing bag-valve-mask equipment at the bedside. Which of the following is the most appropriate initial pharmacologic intervention?

A. Activated charcoal administration
B. Naloxone administration
C. Flumazenil administration
D. Gastric lavage
E. N-acetylcysteine administration

Show answer

The correct answer is B. This patient presents with the classic opioid toxidrome: miosis (pinpoint pupils), severe respiratory depression (rate of 6 breaths/min), SpO2 of 82%, decreased consciousness, bradycardia, and track marks indicating intravenous drug use. In opioid overdose, the primary cause of death is respiratory depression. When respiratory rate is critically low and oxygen saturation is severely compromised, the opioid-specific intervention — naloxone — is the most appropriate initial step because it directly reverses the underlying cause of respiratory depression, miosis, and decreased consciousness by competitively antagonizing opioid receptors. Naloxone can be administered intranasally, intramuscularly, or intravenously and acts within minutes to restore respiratory drive, distinguishing it from supportive measures alone. Note that in a real resuscitation setting, airway support and naloxone are initiated together; however, on USMLE, when the question asks for the 'most appropriate initial step' and the answer choices do not include BVM ventilation as an option, naloxone is the correct targeted intervention. Activated charcoal (A) is used for oral ingestions within 1-2 hours and is contraindicated in an obtunded patient due to aspiration risk; it would also be ineffective for intravenous opioid use. Flumazenil (C) is the reversal agent for benzodiazepine overdose, which typically presents with normal or minimally affected pupil size and less severe respiratory depression, not pinpoint pupils. Gastric lavage (D) is rarely indicated in modern toxicology practice and is not appropriate here given the route of exposure and clinical status. N-acetylcysteine (E) is the antidote for acetaminophen toxicity, which does not present with miosis, respiratory depression, or altered consciousness of this pattern.

Question 2: BASIC CALCULATION

A 52-year-old man with a history of heavy alcohol use (approximately 12 beers daily for 20 years) is admitted to the hospital for elective surgery. He had his last drink 18 hours ago. On examination, he is diaphoretic, tremulous, and anxious. His vital signs show a heart rate of 110/min, blood pressure of 160/95 mmHg, temperature of 38.1°C (100.6°F), and respiratory rate of 22/min. He scores 15 on the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale. Which of the following is the most appropriate pharmacotherapy for this patient?

A. Haloperidol
B. Phenobarbital
C. Chlordiazepoxide
D. Propranolol
E. Clonidine

Show answer

The correct answer is C. This patient is experiencing moderate alcohol withdrawal (CIWA-Ar score of 15, with autonomic hyperactivity, tremor, and anxiety). Benzodiazepines, such as chlordiazepoxide, lorazepam, or diazepam, are the first-line treatment for alcohol withdrawal because they reduce the risk of withdrawal seizures and progression to delirium tremens by acting on GABA-A receptors. Haloperidol (A) is an antipsychotic that lowers the seizure threshold and should not be used as monotherapy in alcohol withdrawal, as it does not prevent seizures. Phenobarbital (B) can be used as an adjunct or alternative in refractory cases but is not first-line due to its narrow therapeutic index and risk of respiratory depression. Propranolol (D) may help control tachycardia and tremor but does not prevent seizures or delirium tremens and should only be used as adjunctive therapy. Clonidine (E) can help manage autonomic symptoms but similarly does not address the underlying GABA deficiency or prevent seizures.

Question 3: INTERMEDIATE

A 28-year-old woman presents to her primary care physician requesting help to quit smoking. She has smoked one pack of cigarettes per day for 10 years. She previously tried to quit "cold turkey" twice but relapsed within 2 weeks each time. She has a history of major depressive disorder that is well-controlled on sertraline. She is motivated to quit and asks about medication options. Which of the following is the most appropriate first-line pharmacotherapy to recommend for smoking cessation in this patient?

A. Varenicline
B. Bupropion
C. Clonidine
D. Nortriptyline
E. Fluoxetine

Show answer

The correct answer is A. Varenicline is a partial agonist at the nicotinic acetylcholine receptor (alpha-4 beta-2 subtype) and has been shown to be the most effective single pharmacotherapy for smoking cessation. It reduces cravings by providing partial stimulation of nicotinic receptors and blocks the rewarding effects of nicotine. Previous concerns about psychiatric side effects have been largely dispelled by the EAGLES trial, making it appropriate even in patients with stable psychiatric conditions. Bupropion (B) is also a first-line option for smoking cessation, but studies have shown varenicline to be superior in head-to-head comparisons; bupropion would still be a reasonable alternative. Clonidine (C) and nortriptyline (D) are second-line agents for smoking cessation and are typically reserved for patients who cannot tolerate first-line therapies. Fluoxetine (E) is an SSRI used for depression and has not been shown to be effective for smoking cessation.

Question 4: APPLIED

A 38-year-old man with a 15-year history of opioid use disorder presents to an outpatient clinic seeking treatment. He has been injecting heroin daily and his last use was 14 hours ago. He reports muscle aches, abdominal cramping, diarrhea, and rhinorrhea. On examination, he has dilated pupils, piloerection, and yawning. His vital signs show a heart rate of 95/min, blood pressure of 145/88 mmHg, and temperature of 37.8°C (100.0°F). He has a history of multiple relapses after completing detoxification programs. He works full-time and wants a treatment that will allow him to maintain his daily routine. Which of the following is the most appropriate long-term treatment for this patient?

A. Methadone maintenance at an opioid treatment program
B. Buprenorphine/naloxone sublingual therapy
C. Naltrexone oral daily therapy
D. Clonidine-assisted detoxification followed by abstinence
E. Inpatient residential rehabilitation for 30 days

Show answer

The correct answer is B. Buprenorphine/naloxone (Suboxone) is a first-line medication-assisted treatment for opioid use disorder that can be prescribed in an outpatient office setting under the Drug Addiction Treatment Act (DATA) waiver, making it ideal for a patient who wants to maintain his daily routine. As a partial mu-opioid agonist, buprenorphine reduces cravings and withdrawal symptoms while having a ceiling effect that limits respiratory depression risk. Methadone maintenance (A) is also highly effective but requires daily visits to a federally regulated opioid treatment program, which would interfere with his work schedule and daily routine. Naltrexone (C) is an opioid antagonist that can be used for relapse prevention but cannot be initiated while the patient is in active withdrawal, as it would precipitate severe withdrawal; additionally, adherence to oral naltrexone is often poor. Clonidine-assisted detoxification (D) only addresses withdrawal symptoms and does not provide long-term relapse prevention; this patient has already relapsed multiple times after detoxification. Inpatient rehabilitation (E) would require him to leave work for an extended period and does not address the need for long-term maintenance pharmacotherapy, which significantly reduces relapse rates.

Question 5: CRITICAL THINKING

A 45-year-old woman is brought to the emergency department by her husband after he found her confused and agitated at home. She has a history of alcohol use disorder and benzodiazepine use disorder. Her husband reports she abruptly stopped drinking alcohol and taking diazepam 3 days ago after an argument. On examination, she is disoriented to time and place, diaphoretic, and tremulous. She intermittently picks at the bedsheets and reports seeing "bugs crawling on the walls." Her vital signs show a temperature of 39.0°C (102.2°F), heart rate of 130/min, blood pressure of 170/105 mmHg, and respiratory rate of 24/min. Laboratory studies show a serum sodium of 140 mEq/L, potassium of 3.2 mEq/L, magnesium of 1.4 mg/dL, and glucose of 110 mg/dL. Despite receiving lorazepam 4 mg IV every 15 minutes for three doses, she continues to be agitated with persistent tachycardia and hypertension. Which of the following is the most appropriate next step in management?

A. Add IV haloperidol for agitation
B. Continue escalating lorazepam doses
C. Add IV phenobarbital as adjunctive therapy
D. Switch to dexmedetomidine infusion
E. Administer IV flumazenil to reverse benzodiazepine effects

Show answer

The correct answer is C. This patient is experiencing benzodiazepine-resistant delirium tremens with concomitant benzodiazepine withdrawal, which explains her refractory presentation despite appropriate initial benzodiazepine dosing. In cases of benzodiazepine-resistant alcohol withdrawal, the addition of phenobarbital as an adjunctive agent is recommended because it acts on a different site of the GABA-A receptor (prolonging chloride channel opening rather than increasing frequency), providing additional GABAergic effect. Adding IV haloperidol (A) may help manage hallucinations and severe agitation as an adjunct, but it does not address the underlying withdrawal physiology, lowers the seizure threshold, and should not be used without adequate GABAergic coverage. Simply continuing to escalate lorazepam doses (B) without adding an adjunctive agent is not the best approach in benzodiazepine-resistant withdrawal, as she has already received 12 mg without improvement, and further escalation alone risks respiratory depression without adequately controlling the withdrawal. Dexmedetomidine (D) is an alpha-2 agonist that can be used as an adjunct in the ICU setting but does not prevent seizures or treat the underlying GABA receptor dysfunction; it is not appropriate as the primary next step. Flumazenil (E) is a benzodiazepine antagonist that would reverse the therapeutic lorazepam and could precipitate life-threatening seizures in a patient undergoing simultaneous alcohol and benzodiazepine withdrawal; this is absolutely contraindicated in this clinical scenario.

SUMMARY

Substance Use & Addiction — Key Concepts Review

Summary

Substance use disorders represent a chronic, relapsing brain disease driven by neuroadaptive changes in the mesocorticolimbic dopamine system. The DSM-5 defines SUD using 11 criteria organized into four domains—impaired control, social impairment, risky use, and pharmacological features—with severity graded as mild (2–3), moderate (4–5), or severe (6+). Tolerance and withdrawal during appropriate medical use do not count toward the diagnosis. Only alcohol and sedative-hypnotic withdrawal are life-threatening; opioid withdrawal is miserable but not fatal.

Management integrates pharmacotherapy and psychosocial interventions. Key medications include naltrexone, acamprosate, and disulfiram for alcohol use disorder; buprenorphine/naloxone, methadone, and naltrexone for opioid use disorder; and varenicline and NRT for tobacco use disorder. SBIRT is the evidence-based approach to universal screening. When evaluating psychiatric symptoms in substance-using patients, distinguish substance-induced disorders (resolve with 2–4 weeks of abstinence) from independent psychiatric illness requiring separate treatment. Approach each patient with the understanding that addiction is a treatable medical condition, not a moral failing.